Immunotherapy plus chemo aims to extend lives in tough lung cancer

NCT ID NCT07418931

Not yet recruiting Disease control Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 108 people who have not had prior treatment will receive the combination. The study is not yet recruiting and will measure survival at one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (an immunotherapy drug) plus chemotherapy (paclitaxel, carboplatin, cisplatin, or gemcitabine)
What this could lead to: If successful, this could offer a new treatment option that improves survival for people with advanced squamous lung cancer.
What could go wrong: This is a small, early-phase trial (108 people) with no results yet. The combination may not work better than standard care, and side effects from chemo and immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER

Contacts and locations

Locations

SC Oncologia Azienda Ospedaliera Santa Croce e Carle di Cuneo

Cuneo, CN, 12100, Italy
SC Oncologia Medica Ospedale Carlo Poma, ASST Mantova

Mantua, MN, 46100, Italy
SC Oncologia Medica Provinciale Azienda USL IRCCS di Reggio Emilia

Reggio Emilia, RE, 42123, Italy
SC di Oncologia Azienda Ospedaliera Santa Maria

Terni, TR, 05100, Italy
SOC Oncologia Medica Nuovo Ospedale Santo Stefano

Prato, PO, 59100, Italy
SOD Oncopneumologia Azienda Ospedaliero Universitaria Pisana

Pisa, PI, 56124, Italy
SSD Gruppo di Patologia Toracica IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Meldola, FC, 47014, Italy
UO Oncologia Clinica Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant' Anna

Cona, FE, 44124, Italy
UOC Oncologia Medica ASST Valle Olona - Ospedale di Saronno

Saronno, VA, 21047, Italy
UOC Oncologia Medica Azienda Ospedaliero-Universitaria di Parma

Parma, PR, 43126, Italy
UOC Oncologia Medica IRCCS Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola

Bologna, BO, 40138, Italy
UOC Oncologia Medica Ospedale San Luca

Lucca, LU, 55100, Italy
UOC Oncologia Medica Ospedale Versilia

Lido di Camaiore, LU, 55041, Italy
UOC Oncologia Medica Ospedale dell'Alta Val d'Elsa

Poggibonsi, SI, 53036, Italy
UOC di Oncologia Medica Azienda Ospedaliero Universitaria di Sassari Ospedale Civile SS. Annunziata

Sassari, SS, 07100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.